Precision medicine company ImpriMed announced it has expanded its services to include human oncology.
The aim is to provide drug response predictions for common blood cancers such as newly diagnosed multiple myeloma and acute myeloid leukemia.
ImpriMed’s human precision medicine services combine genomic analysis, in vitro drug susceptibility testing and machine learning to focus on complex blood cancers.
According to the company’s new survey data: The results of the treatment for untreated non-Hodgkin’s lymphoma will be presented at the EHA-SfPM conference in Copenhagen, Denmark, September 25-27.
“The expansion of Imprimed’s precision medicine services from veterinary medicine to human oncology marks a pivotal milestone in our mission to transform cancer care,” Dr. Seungwon Lim, Imprimed’s chief executive officer, said in a statement.
“By empowering oncologists and researchers to use AI-driven technology to predict treatment outcomes, every patient will have access to truly personalized care. With our expansion into contract research organization services, we aim to aid in the development of new and more personalized cancer treatments, bringing hope to more patients battling cancer.”
Larger trends
In August, Imprimed published a research paper on a new method for measuring cell size in feline lymphoma. Veterinary Medicine: Study data reveals that ImpriMed’s technology has the potential to transform veterinary oncology by improving the accuracy of cell size assessment, providing more reliable prognostic insights and improving treatment plans and patient outcomes.
In May, the company launched ImpriMed Drug Response Predictions, an AI service that predicts anti-cancer drug responses for canine patients with lymphoma or leukemia. DRP is a complement to the company’s Individual Prediction Profiles and features an “Immune Profile” report that provides clonality and immune phenotype data.
